Genus Lifesciences Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENUS LIFESCIENCES
GENUS LIFESCIENCES has eight approved drugs.
There are five US patents protecting GENUS LIFESCIENCES drugs.
Summary for Genus Lifesciences
| US Patents: | 5 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 8 |
Drugs and US Patents for Genus Lifesciences
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | DISCN | Yes | No | 9,539,214 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-010 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,406,108 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-011 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,406,108 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genus Lifesciences
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | 6,926,907 | ⤷ Start Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | 8,206,741 | ⤷ Start Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | 9,364,439 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Lifesciences Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 115139 | ⤷ Start Trial |
| China | 104519888 | ⤷ Start Trial |
| Canada | 2860231 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genus Lifesciences Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
